Feds Votes Not To Approve a Drug in Spite of Patients’ Testimonies

In a 7 – 3 vote, a panel of Food and Drug Administration experts voted against the experimental treatment drug eteplirsen for muscular dystrophy. The FDA committee meeting was packed with families and patients affected by muscular dystrophy with more than 50 speakers including patients, physicians and politicians addressing the panel. Read article here….

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.